Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Role of Akt Activation in PARP Inhibitor Resistance in Cancer

(2020) Ferenc Gallyas Jr et al.   Cancers

Arsenic trioxide-induced p38 MAPK and Akt mediated MCL1 downregulation causes apoptosis of BCR-ABL1-positive leukemia cells

(2020) Chia-Hui Huang et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers

(2020) Timothy A. Yap et al.   Cancer Discovery

The Simpler the Better: Oral Arsenic for Acute Promyelocytic Leukemia

(2019) Hong-Hu Zhu et al.   BLOOD

Ovarian cancer statistics, 2018

(2018) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair

(2015) Qingying Luo et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

(2015) P. A. Konstantinopoulos et al.   Cancer Discovery

Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness

(2015) Pradip De et al.   NEOPLASIA

Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells

(2014) Sanjay Kumar et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Arsenic Trioxide Prevents Osteosarcoma Growth by Inhibition of GLI Transcription via DNA Damage Accumulation

(2013) Shunsuke Nakamura et al.   PLoS One

Evaluating cell lines as tumour models by comparison of genomic profiles

(2013) Silvia Domcke et al.   Nature Communications

Arsenic compounds: revived ancient remedies in the fight against human malignancies

(2012) Jian-Xiang Liu et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

(2012) Ashish Juvekar et al.   Cancer Discovery

The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

(2011) Thomas Helleday   Molecular Oncology

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

The Effects of Arsenic Trioxide on DNA Synthesis and Genotoxicity in Human Colon Cancer Cells

(2010) Jacqueline J. Stevens et al.   International Journal of Environmental Research and Public Health

A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment

(2009) Christopher J. Sweeney et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Acute promyelocytic leukemia: from highly fatal to highly curable

(2008) Z.-Y. Wang et al.   BLOOD

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

Single-strand break repair and genetic disease

(2008) Keith W. Caldecott   NATURE REVIEWS GENETICS